An explorative analysis for the role of serum mir-10b-3p levels in predicting response to sorafenib in patients with advanced hepatocellular carcinoma

Eileen L. Yoon, Jong Eun Yeon, Eunjung Ko, Hyun Jung Lee, Ji Hye Je, Yang Jae Yoo, Seong Hee Kang, Sang Jun Suh, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Kwan Soo Byun

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The prognostic role of aberrant serum miRNA expression for predicting response to sorafenib treatment in advanced hepatocellular carcinoma (HCC) patients has not been well characterized. We aimed to identify specific serum miRNAs that are associated with positive radiologic responses or improved survival in sorafenib-treated HCC patients. miR- 18a, miR-21, miR-139-5p, miR-221, miR-224, and miR-10b-3p, were selected for analysis. Serum samples from 24 patients with advanced stage HCC and 25 patients with liver cirrhosis (LC) were analyzed. All of the miRNAs except miR-21 were found to be upregulated in serum samples from HCC patients. None of the miRNAs assayed differed significantly in terms of expression between the responder and non-responder groups among HCC patients. However, miR-10b-3p levels were significantly higher in the subgroup of HCC patients with worse overall survival (fold change = 5.8, P = 0.008). Serum miRNA-10b-3p was upregulated in the presence of macrovascular invasion (MVI), and those with higher serum miRNA-10b-3p had significantly shorter survival during treatment (P = 0.042). Although no single serum miRNA was predictive of response to sorafenib treatment, analysis of serum miR-10b-3p levels may be valuable for diagnosis of HCC and prediction of survival of sorafenib-treated patients.

Original languageEnglish
Pages (from-to)212-220
Number of pages9
JournalJournal of Korean Medical Science
Volume32
Issue number2
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

MicroRNAs
Hepatocellular Carcinoma
Serum
Survival
sorafenib
Liver Cirrhosis
Therapeutics

Keywords

  • Hepatocellular Carcinoma
  • Macrovascular Invasion
  • Serum MicroRNA
  • Sorafenib
  • Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

An explorative analysis for the role of serum mir-10b-3p levels in predicting response to sorafenib in patients with advanced hepatocellular carcinoma. / Yoon, Eileen L.; Yeon, Jong Eun; Ko, Eunjung; Lee, Hyun Jung; Je, Ji Hye; Yoo, Yang Jae; Kang, Seong Hee; Suh, Sang Jun; Kim, Ji Hoon; Seo, Yeon Seok; Yim, Hyung Joon; Byun, Kwan Soo.

In: Journal of Korean Medical Science, Vol. 32, No. 2, 01.01.2017, p. 212-220.

Research output: Contribution to journalArticle

@article{0d700443e49948c0b32b780d4305a147,
title = "An explorative analysis for the role of serum mir-10b-3p levels in predicting response to sorafenib in patients with advanced hepatocellular carcinoma",
abstract = "The prognostic role of aberrant serum miRNA expression for predicting response to sorafenib treatment in advanced hepatocellular carcinoma (HCC) patients has not been well characterized. We aimed to identify specific serum miRNAs that are associated with positive radiologic responses or improved survival in sorafenib-treated HCC patients. miR- 18a, miR-21, miR-139-5p, miR-221, miR-224, and miR-10b-3p, were selected for analysis. Serum samples from 24 patients with advanced stage HCC and 25 patients with liver cirrhosis (LC) were analyzed. All of the miRNAs except miR-21 were found to be upregulated in serum samples from HCC patients. None of the miRNAs assayed differed significantly in terms of expression between the responder and non-responder groups among HCC patients. However, miR-10b-3p levels were significantly higher in the subgroup of HCC patients with worse overall survival (fold change = 5.8, P = 0.008). Serum miRNA-10b-3p was upregulated in the presence of macrovascular invasion (MVI), and those with higher serum miRNA-10b-3p had significantly shorter survival during treatment (P = 0.042). Although no single serum miRNA was predictive of response to sorafenib treatment, analysis of serum miR-10b-3p levels may be valuable for diagnosis of HCC and prediction of survival of sorafenib-treated patients.",
keywords = "Hepatocellular Carcinoma, Macrovascular Invasion, Serum MicroRNA, Sorafenib, Survival",
author = "Yoon, {Eileen L.} and Yeon, {Jong Eun} and Eunjung Ko and Lee, {Hyun Jung} and Je, {Ji Hye} and Yoo, {Yang Jae} and Kang, {Seong Hee} and Suh, {Sang Jun} and Kim, {Ji Hoon} and Seo, {Yeon Seok} and Yim, {Hyung Joon} and Byun, {Kwan Soo}",
year = "2017",
month = "1",
day = "1",
doi = "10.3346/jkms.2017.32.2.212",
language = "English",
volume = "32",
pages = "212--220",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "2",

}

TY - JOUR

T1 - An explorative analysis for the role of serum mir-10b-3p levels in predicting response to sorafenib in patients with advanced hepatocellular carcinoma

AU - Yoon, Eileen L.

AU - Yeon, Jong Eun

AU - Ko, Eunjung

AU - Lee, Hyun Jung

AU - Je, Ji Hye

AU - Yoo, Yang Jae

AU - Kang, Seong Hee

AU - Suh, Sang Jun

AU - Kim, Ji Hoon

AU - Seo, Yeon Seok

AU - Yim, Hyung Joon

AU - Byun, Kwan Soo

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The prognostic role of aberrant serum miRNA expression for predicting response to sorafenib treatment in advanced hepatocellular carcinoma (HCC) patients has not been well characterized. We aimed to identify specific serum miRNAs that are associated with positive radiologic responses or improved survival in sorafenib-treated HCC patients. miR- 18a, miR-21, miR-139-5p, miR-221, miR-224, and miR-10b-3p, were selected for analysis. Serum samples from 24 patients with advanced stage HCC and 25 patients with liver cirrhosis (LC) were analyzed. All of the miRNAs except miR-21 were found to be upregulated in serum samples from HCC patients. None of the miRNAs assayed differed significantly in terms of expression between the responder and non-responder groups among HCC patients. However, miR-10b-3p levels were significantly higher in the subgroup of HCC patients with worse overall survival (fold change = 5.8, P = 0.008). Serum miRNA-10b-3p was upregulated in the presence of macrovascular invasion (MVI), and those with higher serum miRNA-10b-3p had significantly shorter survival during treatment (P = 0.042). Although no single serum miRNA was predictive of response to sorafenib treatment, analysis of serum miR-10b-3p levels may be valuable for diagnosis of HCC and prediction of survival of sorafenib-treated patients.

AB - The prognostic role of aberrant serum miRNA expression for predicting response to sorafenib treatment in advanced hepatocellular carcinoma (HCC) patients has not been well characterized. We aimed to identify specific serum miRNAs that are associated with positive radiologic responses or improved survival in sorafenib-treated HCC patients. miR- 18a, miR-21, miR-139-5p, miR-221, miR-224, and miR-10b-3p, were selected for analysis. Serum samples from 24 patients with advanced stage HCC and 25 patients with liver cirrhosis (LC) were analyzed. All of the miRNAs except miR-21 were found to be upregulated in serum samples from HCC patients. None of the miRNAs assayed differed significantly in terms of expression between the responder and non-responder groups among HCC patients. However, miR-10b-3p levels were significantly higher in the subgroup of HCC patients with worse overall survival (fold change = 5.8, P = 0.008). Serum miRNA-10b-3p was upregulated in the presence of macrovascular invasion (MVI), and those with higher serum miRNA-10b-3p had significantly shorter survival during treatment (P = 0.042). Although no single serum miRNA was predictive of response to sorafenib treatment, analysis of serum miR-10b-3p levels may be valuable for diagnosis of HCC and prediction of survival of sorafenib-treated patients.

KW - Hepatocellular Carcinoma

KW - Macrovascular Invasion

KW - Serum MicroRNA

KW - Sorafenib

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85011636509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011636509&partnerID=8YFLogxK

U2 - 10.3346/jkms.2017.32.2.212

DO - 10.3346/jkms.2017.32.2.212

M3 - Article

C2 - 28049231

AN - SCOPUS:85011636509

VL - 32

SP - 212

EP - 220

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 2

ER -